Skip to main content

Table 2 Compliance with QOL assessment

From: Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

  PC group (n = 34) VGD group (n = 34)
Assessment time Baseline 6 week 12 week 18 week Baseline 6 week 12 week 18 week
No. of evaluable patients 34 34 23 13 34 34 24 20
Discontinuation of protocol treatment 0 0 11 10 0 0 10 4
Investigator's error 0 1 1 1 0 1 0 1
No reason provided 0 0 0 0 0 0 1 1
No. of submitted questionnaires
Compliance (%)
34
100%
33
97%
22
96%
12
92%
34
100%
33
97%
23
96%
18
90%